We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Filing Updates | China Securities Regulatory Commission: 5 Companies Planning to List in Hong Kong/US Required to Submit Additional Filing Materials (May 26, 2023 - June 1, 2023) (Detailed Requirement

Filing Updates | China Securities Regulatory Commission: 5 Companies Planning to List in Hong Kong/US Required to Submit Additional Filing Materials (May 26, 2023 - June 1, 2023) (Detailed Requirement

On June 2, 2023, the official website of the China Securities Regulatory Commission (CSRC) publicly announced the supplementary material requirements for overseas issuance and listing filings (from May 26, 2023 to June 1, 2023). The International Department issued supplementary material requirements to a total of 5 companies. Xiaojin believes that this review feedback document is of reference significance for enterprises planning to go public overseas in preparing relevant documents and is worth noting!

image.png

Image source: Official website of the China Securities Regulatory Commission

It is reported that among the five companies required to submit supplementary filing materials this time, Wanda Commercial Management and Genecast Group Inc. (Zhenhe Medical) plan to list via IPO in Hong Kong, Fangzhou Inc. (Fangzhou Pharmaceuticals) plans to list via IPO in Hong Kong, and Global Mofy Metaverse Limited (Global Mofy) and U-BX (Youjia Insurance) plan to list via IPO on NASDAQ in the United States.

The specific supplementary material requirements for overseas issuance and listing filings issued by the International Department of the CSRC to these 5 enterprises are as follows:

Zhuhai Wanda

I. Please supplement and explain the operation of corporate governance and internal control, whether the internal control system is sound and effective, whether there are instances of funds being occupied by the controlling shareholder or other related parties, and whether there are instances of external guarantees and guarantees provided for the controlling shareholder. Please also explain the relevant internal control systems and safeguard measures to prevent the occupation of funds by related parties and avoid providing guarantees for the controlling shareholder.

II. According to your company's prospectus, the average occupancy rate of the commercial square under your company's management from 2019 to 2021 was 98.8%. Please explain the calculation standard and accuracy of the above occupancy rate in combination with the actual collection status of your company's commercial management service fees and rents during the reporting period and the comparable situation of peer companies in the same period (if any); please explain whether there are effective measures in your company's assessment and internal control system to prevent internal personnel from falsely reporting the occupancy rate and collection rate and the actual implementation status.

III. Please explain the related party transactions and capital transactions between your company and the controlling shareholder and other related parties during the reporting period, the proportion of such related party transactions in your company's operating revenue or operating cost during the reporting period, and the independence of your company's business.

IV. Please explain the reasons for the substantial increase in revenue and profit during the reporting period and the subsequent collection status of relevant receivables in combination with indicators such as the change in the controlling shareholder's project operation mode, receivables during the reporting period, and cash flow from operating activities. Please explain the short-term solvency risk of your company's controlling shareholder in combination with the equity repurchase, early debt repayment and other arrangements made by your company and the controlling shareholder regarding your company's listing time and performance realization.

V. Please specify the safeguard measures and relevant arrangements taken to strengthen the management of the use of raised funds and refine the purpose of the raised funds; and issue a commitment that the raised funds from this issuance and listing will not directly or indirectly flow into the real estate development field.

VI. According to the prospectus, your company's cumulative cash dividends during the reporting period (from 2019 to 2021 and the first half of 2022) amounted to 13.273 billion yuan, exceeding the total net cash flow from operating activities of 11.548 billion yuan in the same period. In addition to the above dividends, the shareholders' meeting on September 23, 2022 approved a proposal for a dividend of 3.478 billion yuan; after listing, the board of directors also intends to propose to the shareholders' meeting that at least 65% of the annual distributable profit be used for dividends. Please explain the rationality of the cash dividend amount during the reporting period and the future cash dividend policy, whether there is a significant impact on the company's solvency and sustainable operation ability, and the necessity and rationality of implementing this financing under the circumstance of large cash dividends.

VII. Please timely supplement and update the filing materials for this round in conjunction with the updated content of the prospectus.

Global Mofy Metaverse Limited

I. Please, in accordance with the requirements of the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing Category No. 2: Guidelines on the Content and Format of Filing Materials", provide a detailed explanation of the establishment of your company and the changes in share capital and shareholders since its establishment, including but not limited to capital increase and share subscription, share transfer and related payment status, and provide the basis.

II. Please supplement the specific basis for determining the company's major domestic operating entities, including but not limited to the specific proportion of relevant financial statement data accounted for by the major domestic operating entities in your company, and explain whether there are other major operating entities.

III. Regarding the equity structure, please supplement: (1) the compliance of the establishment of the relevant equity structure, including but not limited to the status of regulatory procedures such as foreign exchange administration and overseas investment involved in the structure establishment and round-trip M&A, and the status of taxes and fees paid in accordance with the law; (2) the specific transaction arrangements between the relevant entities under such structure, including but not limited to the time, amount, channel and method of capital support for domestic entities, and the status of relevant capital flows and profit transfer arrangements; (3) the specific circumstances and reasons for Ren Zhenquan, the actual controller of your company's shareholder MOFY YI LIMITED, failing to perform the regulatory procedures related to overseas investment by domestic residents, and the subsequent rectification measures (if applicable), and whether such circumstances constitute a material impact on this issuance and listing.

IV. Regarding the payment of registered capital, please supplement: (1) the actual payment status of the registered capital of your company's shareholders such as United Cosmos Investment Holding Group Co., Ltd.; (2) the status of unpaid or insufficiently paid registered capital of your company's invested and controlled companies such as Global Mofy (Beijing) Technology Co., Ltd.; (3) the reasons for the insufficient payment of such registered capital, and whether it will constitute a material impact on this issuance and listing.

V. Regarding the situation that your company's actual controller controls the company through a trust, please supplement: (1) the complete penetration situation of your company's controlling shareholder JAMES YANG MOFY LIMITED; (2) the main contents of the relevant contracts and asset management arrangements involving the upper-level trust Smart Executive Developments Limited of your company's controlling shareholder JAMES YANG MOFY LIMITED, including but not limited to the specific form of the trust, the trust management authority, trust or asset management fees, the term of the contract and the conditions for modification and termination, the arrangement for handling trust assets, the time of signing the contract and other special clauses, the time and method of changes in the shares held by the actual controller in the listed company, etc.

VI. Regarding the company's main business involving the metaverse concept and virtual technology, please supplement: (1) whether your company's business involves or supports virtual asset transactions, and explain the specific situation and compliance (if applicable); (2) whether there are relevant data and information security risks involved in the metaverse concept related to your company's technology, and provide relevant basis; (3) whether there are circumstances prohibited by relevant laws and regulations in your company's main business and the operation involving the metaverse concept, and provide relevant basis.

VII. Please supplement the penetration situation of non-natural person shareholders of domestic operating entities such as Global Mofy (Beijing) Technology Co., Ltd. since its establishment, whether the price of each equity change is fair, and provide the basis; whether there is any affiliation between shareholders, and whether there is any entrusted shareholding or other interest transfer situation.

U-BX (Youjia Insurance)

I. Regarding the equity structure: (1) Please explain the compliance of the equity structure establishment, including but not limited to the regulatory procedures such as foreign exchange management and overseas investment involved in the establishment and round-trip M&A, and the payment of taxes and fees in accordance with the law; 10 shareholders and actual controllers of your company, including Liu Jiangmei, have not yet completed the registration in accordance with the Circular No. 37. Please explain the impact of the failure to complete the registration on the company's issuance and listing and the relevant follow-up arrangements; (2) Please explain the specific transaction arrangements between the relevant entities under the equity structure, including but not limited to the time, amount, channels and methods of capital support for domestic entities, as well as the relevant capital flows and profit transfer arrangements; (3) Your company issued additional shares in May 2022 to introduce two shareholders, and the actual controllers of the two shareholders, Liu Jiangmei and Li Wenchao, subscribed for shares in US dollars through overseas bank accounts. Please explain the source and compliance of the overseas funds.

II. Regarding equity changes and paid-in capital: (1) Please explain the capital contribution prices and pricing basis of each capital increase and equity transfer since the establishment, including the price of technology contribution, whether the capital contribution is paid in full, and whether there are defects such as failure to fulfill capital contribution obligations,抽逃出资, and problems with capital contribution methods; (2) Your company mainly conducts business through domestic operating entities. According to the filing materials, the registered capital of your company's domestic operating entity Youjia Youbao (Beijing) Technology Co., Ltd. is currently only about 8% paid in, and the paid-in capital of Jiangsu Jingmo Technology Co., Ltd., Jiangsu Youjia Youche Technology Co., Ltd. and others is 0. Please supplement and explain whether the insufficient paid-in registered capital will adversely affect the normal business development and debt solvency of the domestic operating entity.

III. Please explain the specific listing plan.

IV. Please supplement and explain the relevant qualifications or licenses required for compliant operation in China.

V. Please explain the products such as mini-programs developed and operated by your company, the scale of user information collected and stored, the collection and use of data, whether there are circumstances where information is provided to third parties, and the arrangements or measures for personal information protection and data security before and after listing.

Genecast Group Inc. (Genecast Medical)

I. Regarding the contractual control structure, please verify and explain: (1) The compliance of the establishment of the contractual control structure, including but not limited to the regulatory procedures such as foreign exchange management and overseas investment involved in the establishment and round-trip M&A, and the payment of taxes and fees in accordance with the law; (2) The specific transaction arrangements between the relevant entities under the contractual control structure, including but not limited to the time, amount, channels and methods of capital support for domestic entities, as well as the relevant capital flows and profit transfer arrangements;

II. Regarding equity changes, please verify and explain: (1) The similarities and differences between the issuer's angel round preferred shares, Series A preferred shares, Series B preferred shares, Series C1 preferred shares, Series C2 preferred shares, Series D preferred shares, and Series E preferred shares, whether there are differences in the capital increase prices, and the reasons and rationality for the differences in the capital increase prices; (2) List the amount, payment status, determination basis, tax payment status, and the fulfillment of domestic regulatory procedures such as foreign exchange management and overseas investment for each equity change of the issuer and its domestic operating entity since its establishment.

III. Regarding shareholder status, please verify and explain: (1) Whether the actual owners of the shares held by Cai Lingya and Liu Guowei on behalf of others include entities prohibited by laws and regulations from holding shares of the issuer directly or indirectly, and whether there is profit transfer; (2) Please specify the relationship between Cai Lingya and Kaifeng Changyang Venture Capital, Nanjing Kaiyuan, Kaitai Venture Capital, and Kaifeng Zhide; (3) Gao Cailing held shares of the issuer's domestic operating entity from November 2014 to January 2017. Please confirm whether this is a proxy holding and the reason; if it is a proxy holding, please explain the status of the actual owners of the shares, the reason for the proxy holding, whether there are entities prohibited by laws and regulations from holding shares of the issuer directly or indirectly, and whether there is profit transfer or conflict of interest; (4) The time when the issuer's shareholder EverestLu Holding Limited and its wholly-owned parent company National Development Fund are expected to complete the state-owned asset management procedures.

IV. Regarding your company's sales model, please verify and explain the form of contact and cooperation between your company and hospitals, KOLs, and doctors, the payment costs, and whether there are circumstances that constitute commercial bribery or unfair competition.

V. Regarding the employee stock ownership plan and equity incentive, please verify and explain: (1) The names, commencement time of employment, current positions, whether formal employment contracts have been signed with your company, and the number and price of equity granted to the 270 incumbent employees participating in the equity incentive plan; (2) The start and end dates of employment at your company, the units they belonged to during their tenure at your company, the positions they held, and the equity price granted to the 2 departing employees participating in the equity incentive plan; (3) The employer and position of external personnel participating in the equity incentive plan; (4) The source of funds for the aforementioned relevant personnel to obtain shares, whether regulatory procedures such as foreign exchange management and overseas investment have been fulfilled, and whether there is any affiliation with doctors, KOLs, hospitals, or their key decision-makers who have cooperation with your company; (5) Whether there are currently natural persons or legal persons other than the aforementioned 270 natural persons enjoying the trust interests of your company's three equity incentive plans.

VI. Please verify and explain whether your company's product R&D and business operations, and other activities need to fulfill relevant regulatory procedures for the management of human genetic resources, and whether they comply with the relevant provisions of Articles 7 and 21 of the "Regulations of the People's Republic of China on the Management of Human Genetic Resources".

Fangzhou Inc. (Fangzhou Medical)

I. Regarding the shareholder penetration situation, please explain the specific situation of penetrating the controlling shareholder, actual controller, shareholders holding more than 5% of shares, shareholder directors, supervisors, and senior management to natural persons, and whether there are circumstances such as entities prohibited from holding shares by laws and regulations. Where shareholding is involved through trusts or agreement arrangements, please explain the situation of all beneficiaries; where limited liability companies are involved, please explain the situation of all shareholders.

II. Regarding the contractual control structure, please explain: (1) The compliance of the establishment of the contractual control structure, including but not limited to the fulfillment of regulatory procedures such as foreign exchange management and overseas investment involved in the establishment and round-trip M&A, and the payment of taxes and fees in accordance with the law; (2) The specific transaction arrangements between relevant entities under the contractual control structure, including but not limited to the time, amount, channels, and methods of capital support for domestic entities, and relevant situations such as capital transactions and profit transfer arrangements.

III. The compliance of your company's acquisition of relevant equity interests in major domestic operating entities, including but not limited to the fulfillment of regulatory procedures such as foreign exchange management and foreign investment, and internal decision-making procedures.

IV. Please supplement and explain the compliance of setting aside reserved interests in the equity incentive plan, including but not limited to the fulfillment of domestic regulatory procedures such as foreign exchange management, the determination methods and basis of incentive objects, exercise prices, and exercise conditions, the situation of incentivizing external personnel, whether there are circumstances involving the transfer of benefits, and state the basis for verification.

V. According to the prospectus, the amount of your company's purchase of goods or services from related parties in 2020 was 643 million yuan, and the amount of advances and loans to related parties in 2020 and 2021 was 81 million yuan and 37 million yuan respectively. Please supplement and explain the necessity, rationality, and fairness of the aforementioned related party transactions, whether necessary internal decision-making procedures have been fulfilled, and whether there are circumstances such as the transfer of benefits and occupation of funds.

VI. Please supplement and explain whether your company and its domestic operating entities that actually operate online audio-visual program services have the relevant qualifications.

VII. Please supplement and explain the changes in your company's shareholding structure, organizational structure, and business before and after the shareholder dispute event in 2019, whether complete internal decision-making procedures have been fulfilled, and whether there are major ownership disputes over the shares held by the controlling shareholder or shareholders controlled by the controlling shareholder or actual controller.

8. According to the filing report, your company engages in the sales of both prescription and over-the-counter drugs. Please explain whether your company complies with the "Measures for the Supervision and Administration of Online Drug Sales" by combining aspects such as drug quality and safety management, the filing situation with the competent authorities, and information disclosure.

9. Please supplement and explain the reasons for the unpaid registered capital of your company's main domestic operating entity and its compliance.

Originally published on 金盒企业管理集团